3B BlackBio Dx Ltd announced its FY26 consolidated profit of Rs 59.92 crore and declared a dividend of Rs 5 per share at its 54th AGM. The company reported operational revenue of Rs 141.91 crore, bolstered by 36% growth in its UK subsidiary and the integration of Coris BioConcept. While management targets 15-20% growth for FY27, investors should keep an eye on pricing pressures from rising market competition and the status of ongoing international M&A efforts.
3B BlackBio Dx FY26 Financial Results and Dividend Announcement
Revenue from Operations reached Rs 141.91 Crore; Profit After Tax stood at Rs 59.92 Crore.
Reader Takeaway: Strong UK market expansion offsets pricing competition; focus shifts to US M&A and Digital PCR innovation.
What just happened
3B BlackBio Dx successfully concluded its 54th Annual General Meeting, where shareholders approved the adoption of financial statements and a final dividend of Rs 5.00 per share for the 2025-26 fiscal year. The company reported a solid financial performance with a Profit After Tax (PAT) of Rs 59.92 crore on a consolidated revenue of Rs 141.91 crore.
Why this matters
The results highlight the successful integration of Coris BioConcept, acquired in August 2025, which is now a core contributor to the company’s financials. Furthermore, the company’s UK subsidiary, TRUPCR Europe, continues to be a high-growth engine, posting a 36% year-on-year sales increase, reaching £1.75 million.
What changes now
Management has issued a growth guidance of 15%-20% for FY 2026-27, driven by its molecular diagnostics (MDx) portfolio. The company is also moving toward IVDR certification for its Class C products, a critical regulatory milestone to maintain its competitive edge in European markets. Additionally, the company has officially launched a search for M&A targets in the US market.
Risks to watch
The MDx industry is witnessing intensifying competition, which has put pressure on pricing. Geopolitical instability in the Middle East has previously hampered export orders, and the company’s ambitious US M&A strategy remains subject to finding suitable targets. Management indicated that if no acquisition is finalized within two years, the capital allocation strategy may be re-evaluated.
Context metrics
- Earnings Per Share (EPS): Rs 69.94
- Profit Before Tax: Rs 76.96 Crore
- R&D Expenditure Growth: 46% Year-on-Year
- UK Subsidiary 4-Year CAGR: 57.20%
What to track next
Watch for updates on the IVDR certification process for TRUPCR products and any formal announcements regarding potential US-based acquisitions. Monitoring margin stability in light of rising market competition will be crucial for the next two quarters.